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Abstract
Tolerance to the antinociceptive effect of mu-opioid receptor (MOPr) agonists, such as
morphine and fentanyl, greatly limits their effectiveness for long-term use to treat pain.
Clinical studies have shown that combination therapy and opioid rotation can be used to
enhance opioid-induced antinociception once tolerance has developed. The mechanism
and brain regions involved in these processes are unknown. The purpose of this study
was to evaluate the contribution of the ventrolateral periaqueductal gray (vlPAG) to
antinociceptive tolerance and cross-tolerance between administration and coadministration of morphine and fentanyl. Tolerance was induced by pretreating rats with
morphine or fentanyl or low-dose combination of morphine and fentanyl into the vlPAG
followed by assessment of cross-tolerance to the other opioid. In addition, tolerance to
the combined treatment was assessed. Cross-tolerance did not develop between
repeated vlPAG microinjections of morphine and fentanyl. Likewise, there was no
evidence of cross-tolerance from morphine or fentanyl to co-administration of morphine
and fentanyl. Co-administration did not cause cross-tolerance to fentanyl. Crosstolerance was only evident to morphine or morphine and fentanyl combined in rats
pretreated with co-administration of low-doses of morphine and fentanyl. In conclusion,
cross-tolerance does not develop between morphine and fentanyl within the vlPAG.
This finding is consistent with the functionally selective signaling that has been reported
for antinociception and tolerance following morphine and fentanyl binding to the MOPr.
This research supports the notion that combination therapy and opioid rotation may be
useful clinical practices to reduce opioid tolerance and other side effects.
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Perspective: This preclinical study shows that there is a reduction in cross tolerance
between morphine and fentanyl within the periaqueductal gray which is key brain region
in opioid antinociception and tolerance.
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HIGHLIGHTS
•

The periaqueductal gray is site of action for reduced opioid cross-tolerance

•

Co-administration of low-dose opioids can enhance antinociception

•

Lack of cross-tolerance to opioids supports the clinical use of opioid
rotation
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Introduction
Morphine and fentanyl are two of the most commonly used drugs to treat pain.
Chronic use is limited by unpleasant side effects and the development of tolerance.
Opioid rotation and co-administration have been used to enhance pain relief and limit
these side effects 28, 44. Although animal studies report additive antinociceptive effects
when morphine and fentanyl are co-administered 5, 39, clinical research indicates that
the analgesic efficacy of co-administered morphine and fentanyl is greater than
administration of either opioid alone 28, 47. This effect appears to be the result of
maintained fentanyl potency despite the development of tolerance to morphine
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Many preclinical studies evaluating cross-tolerance between morphine and
fentanyl show enhanced antinociception and reduced tolerance when one opioid is
substituted for the other 10, 35, 36, 43. Other studies show cross-tolerance with as little as a
single injection, as well as with continuous administration 26, 40. Route and length of
administration may be key factors in the analgesic efficacy of co-administered opioids.
Opioids produce antinociception by binding to mu-opioid receptors at sites
throughout the nervous system. Microinjection of either morphine or fentanyl into the
ventrolateral periaqueductal gray (vlPAG) produces antinociception 3 and repeated
administration of either drug results in tolerance to this antinociception 1. Despite these
similarities, the intracellular signaling molecules appear to be distinct. Tolerance to
repeated morphine injections into the vlPAG is mediated by C-Jun N –terminal kinase
(JNK), whereas tolerance to repeated fentanyl microinjections is mediated by G protein–
coupled receptor kinase (GRK) 32. This difference suggests that within the vlPAG there
should be no cross-tolerance between morphine and fentanyl microinjections. This
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hypothesis will be tested by microinjecting rats with morphine, fentanyl, or a
combination of morphine and fentanyl directly into the vlPAG.
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Methods
Subjects
Experiments were performed on male Sprague-Dawley rats (n = 93) with a mean
weight of 277g (230 – 330g). Prior to surgery rats were double housed on a 12-hour
light-dark cycle (lights on at 7AM). Food and water were available at all times except
during testing. All procedures were approved by the Washington State University
Animal Care and Use Committee and conducted in accordance with the guidelines for
animal use described by the International Association for the Study of Pain.

Stereotaxic Surgery and Microinjections
Rats were anesthetized with pentobarbital (60 mg/kg, i.p.) and implanted
unilaterally with a guide cannula (23 gauge; 9 mm long) aimed at the vlPAG using
stereotaxic techniques (AP: +1.7 mm, ML: ±0.6 mm, DV: -4.6 mm from lambda).
Following surgery, the guide cannula was occluded with a 9 mm stylet. Rats were
handled daily following surgery. Morphine sulfate (a gift from the National Institute on
Drug Abuse) and fentanyl citrate (Sigma-Aldrich), were dissolved in sterile saline. Drugs
were administered through a 31-gauge injection cannula inserted into and extending 2
mm beyond the guide cannula. One day prior to testing, the injector was inserted into
the guide cannula without drug administration to habituate them to the procedure and
prevent mechanical activation of neurons on the test day.
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Behavioral testing
Nociception was assessed using the hot plate test in which the latency for the rat to
lick the hind paw was measured when placed on a 52.5°C hotplate. The rat was
removed if no response occurred within 50 s. Rats with a baseline hot plate latency
greater than 25 s were not included in data analysis. Rats were randomly assigned and
injected into the vlPAG with either 0.9% saline (0.4 μL), morphine (5 μg/0.4 μL), fentanyl
(3 μg/0.4 μL), or a morphine/fentanyl combination (2.5 μg of morphine and 1.5 μg of
fentanyl in 0.4 µl). These combination doses were chosen as half the ED50 dose for
each opioid so as to result in an equiantinociceptive dose compared to each opioid
alone. Nociception was assessed in a subset of rats at 5, 30, & 60 minutes after the first
injection to determine optimal test time in tolerance experiments. Tolerance was
established by repeated injections of either drug alone or the combination twice a day
for two days 1. Nociceptive testing was only conducted following the first and the last
injections to prevent the development of behavioral tolerance
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Only male rats were

used given that tolerance mediated by PAG is minimal in female rats 20.
The presence of tolerance was assessed on Day 3 using a cumulative dosing
procedure 31. Increasing third log doses of morphine (cumulative doses of 1, 2.2, 4.6,
10, 22 μg/0.4 μL), fentanyl (cumulative doses of 0.46, 1, 2.2, 4.6 & 10 μg/0.4 μL), or a
combination of morphine (0.5, 1.1, 2.3, 5, & 11 μg/0.4 μL) and fentanyl (0.23, 0.5, 1.1,
2.3, & 5 μg/0.4 μL) was microinjected into the vlPAG. Half of the cumulative dose of
morphine and fentanyl was used at each step when co-administered. The timing for
cumulative dosing for morphine and fentanyl alone have been established previously
31

3,

as follows morphine was injected at 20 min intervals followed by hot plate testing 15
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min after each injection. Fentanyl was injected at 4 min intervals with behavioral testing
2 min after each injection. Co-administered of morphine and fentanyl was injected at 7
min intervals to capture peak antinociception of the combination within the time course
of both drugs (see Fig. 2). Rats were tested on the hot plate 5 min after each injection.
Tolerance was defined as a significant rightward shift in the dose response curve by
comparing ED50 values for rats pretreated with an opioid vs. the saline vehicle.

Histology and data analysis
Following testing, rats received a lethal dose of Halothane. Brains were removed
and stored in formalin (10%). At least 2 days later the brain was sliced coronally (100
μm) to determine the location of the injection site 37. Only those injections in or
bordering the vlPAG were included in data analysis (Figure 1). Dose-response curves
were plotted using GraphPad (Prism 6) and the half maximal antinociceptive effect
(ED50) was calculated for each group 1. ANOVAs were used to determine statistically
significant differences between groups (α < 0.05). Data are presented as mean ± SEM
unless otherwise stated. A Bonferroni post-hoc analysis was used when necessary to
compare two means.
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Results
Opioid-induced antinociception in vlPAG
A subset of rats used in each of the tolerance experiments were tested before and
5, 30, and 60 minutes after opioid administration to determine the time course for
antinociception to co-administration of morphine and fentanyl. There were no significant
differences in baseline hot plate latencies between groups prior to drug administration
(F(3, 28) = 2.24 p = 0.11). Microinjection of morphine (5 μg/0.4 μL), fentanyl (3 μg/0.4 μL),
and combined morphine/fentanyl (2.5 μg & 1.5 μg/0.4 μL) into the vlPAG caused a
significant increase in hot plate latency compared to saline controls (Figure 2; F(3, 143) =
22.97; p < 0.05). Administration of morphine and combined morphine/fentanyl produced
antinociception at 5, 30, and 90 min post injection compared to saline controls.
Microinjection of fentanyl alone had a rapid onset and offset, producing a significant
increase in hot plate latency compared to saline only at the 5 min time point (Bonferroni;
p < 0.05).

Lack of cross-tolerance between morphine and fentanyl in vlPAG
Repeated microinjections of fentanyl twice daily for 2 days did not cause a
significant change in morphine potency on Day 3 compared to saline treated controls
(Figure 3a; F(1, 76) = 1.66; p = 0.20). Morphine potency was 4.2 ± 1.04 µg (N = 8) and 3.2
± 0.96 µg (N = 8) following pretreatment with fentanyl or saline, respectively. Similarly,
pretreatment with morphine did not cause a significant change in fentanyl potency
(Figure 3b; F(1, 71) = 1.93, p = 0.17). Fentanyl potency was 1.7 ± 0.67 µg (N = 7) and 2.4
± 0.57 µg (N = 8) following pretreatment with morphine or saline, respectively. The lack
9

of cross-tolerance between morphine and fentanyl is consistent with previous studies
showing distinct intracellular mechanisms for tolerance to morphine and fentanyl
antinociception 26, 32.

Co-administration of morphine and fentanyl
Co-administration of morphine and fentanyl for two days caused cross-tolerance to
morphine, but not fentanyl antinociception. Pretreatment with morphine and fentanyl
caused a significant rightward shift in the morphine dose-response curve compared to
rats pretreated with saline (Figure 4a; F(1, 66) = 6.96; p < 0.05). Morphine ED50 was 12.5
± 3.69 µg in rats pretreated with co-administered morphine/fentanyl compared to 6.2 ±
2.35 µg in rats pretreated with saline. In contrast, co-administration of morphine and
fentanyl did not alter the fentanyl dose-response curve (Figure 4b). There was no
significant difference in the antinociceptive potency of fentanyl (3.7 ± 0.52 vs. 3.9 ±
0.73) in rats pretreated with co-administered morphine/fentanyl or saline, respectively
(F(1, 76) = 0.14; p = 0.70).
Cross-tolerance was not evident when the experiment was conducted in the
opposite direction. That is, pretreatment with morphine or fentanyl for two days did not
cause a shift in the combined morphine/fentanyl dose-response curve (Figure 5a; F(2,
114)

= 1.03; p = 0.36). Pretreatment with morphine or fentanyl alone caused log shifts to

co-administered morphine/fentanyl of only 0.07 and -1.0, respectively. However,
combined pretreatment with morphine and fentanyl caused a rightward shift in the
combined dose-response curve on Day 3 (Figure 5b; F(1, 76) = 9.91; p < 0.05). This
tolerance was evident by a full one-third log shift in the combined morphine/fentanyl
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ED50. This was the largest rightward shift in the dose response curve for any of the
drug combinations (Table 1).
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Discussion
The current study found that cross-tolerance did not develop between morphine
and fentanyl when microinjected into the vlPAG using the same paradigm that produces
tolerance to each drug alone 1, 31, 45. In addition, rats treated with either opioid alone did
not show tolerance to the co-administration of morphine and fentanyl. Only two
conditions resulted in antinociceptive tolerance; pretreatment with low dose combination
of both opioids followed by testing with the same combination or with morphine alone
(Table 1).
A lack of cross-tolerance between morphine and fentanyl has also been reported
following systemic administration 10, 35, 36, 43. The clinical use of fentanyl to treat
breakthrough pain in patients undergoing chronic opioid treatment also suggests a lack
of cross-tolerance between fentanyl and other opioids 9, 18, 33. Co-administration of
fentanyl is frequently used to reestablish pain relief when tolerance has developed to a
particular opioid 27, 47. In addition to enhancing analgesia, co-administration of opioids
has been reported to reduce side effects such as nausea, vomiting, and sedation 24, 28,
38, 41.

The lack of cross-tolerance between morphine and fentanyl suggests that these two
opioids act at different sites and/or via different mechanisms. Our studies showing a
lack of cross-tolerance between morphine and fentanyl when injected into the vlPAG
supports the hypothesis that different mechanisms are engaged. The vlPAG plays an
important role in opioid antinociception and tolerance 1, 29, 45. In addition, the lack of
cross-tolerance when rats are pretreated with a single opioid(morphine or fentanyl) and
then given the co-administration also suggests distinct neural mechanisms underlie
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tolerance to each drug. The important implication of this experiment is that lower doses
of the opioids can be used for effective antinociception after tolerance has developed to
a single opioid. However, when both morphine and fentanyl are combined during
pretreatment and tolerance assessment, we find tolerance does develop, likely because
both morphine and fentanyl tolerance mechanisms are being activated. An interesting
finding is that rats pretreated with repeated co-administration of morphine and fentanyl
produces cross-tolerance to morphine alone, but not fentanyl alone. This may be
attributed to the half doses that were used in the co-administration pretreatment
compared to when the drugs were administered alone. It is possible that the dose of
fentanyl used in the pretreatment is inadequate to induce tolerance, whereas the dose
used for morphine is sufficient to induce tolerance.
A potential contributing factor to the lack of cross-tolerance between opioids is that
the affinity and efficacy at the MOPr differs between agonists. It has been shown that
MOPr agonists bind and activate different splice variants of the MOPr, which may be
linked to the ligand-biased effects seen in this study. Fentanyl, but not morphine
antinociception is blocked following deletion of a particular exon on the MOPr, although
the MOPr isoforms in the vlPAG have not been identified

34.

In addition, the formation of

heterodimers (e.g., MOPr/DOPr) could contribute to downstream signaling involved in
tolerance for the different opioids 8.
Morphine and fentanyl also differ in efficacy. Morphine efficacy is lower than that of
fentanyl whether assessed with [35S]GTPγS 23, 25, 46 or when assessing the
antinociceptive effects following systemic or intrathecal administration

22, 30.

The

relationship between efficacy and antinociceptive tolerance is not clear because efficacy
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correlates with MOPr internalization 12. Efficacy is unlikely to have an effect on the lack
of cross-tolerance reported here because we have found that morphine and fentanyl
have equal antinociceptive efficacies when microinjected into the vlPAG 1.
These initial differences in receptor coupling and regulation may lead to differences
in activation of signaling cascades and tolerance development. Ligand-biased signaling
at the MOPr is the most likely explanation for the lack of cross-tolerance between
morphine and fentanyl 25. Morphine is typically inferior to fentanyl in inducing MOPr
phosphorylation, desensitization, and internalization. Fentanyl causes phosphorylation
of the MOPr via GRK, whereas morphine uses a PKC mediated mechanism
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In many

tissue preparations morphine is very weak at inducing MOPr internalization compared to
other agonists such as fentanyl 6, 7, 25, 26, 48. This functionally selective difference in
signaling has been shown to alter morphine and fentanyl antinociception. Blockade of
MOPr internalization with dyn-DN had no effect on morphine antinociception, but
enhanced fentanyl antinociception 2. In contrast, inhibition of Gαi/o-proteins by pertussis
toxin (PTX) caused a reduction in morphine, but not fentanyl-induced antinociception 4,
14, 15.

Blockade of a component of β-arrestin signaling (i.e. G-protein receptor kinase or
extracellular signal regulated kinase) has been shown to prevent tolerance to agonists,
such as fentanyl, and have no effect on tolerance to morphine

2, 16, 21, 26, 32.

In contrast,

inhibition of proteins downstream of G-protein signaling (i.e. protein kinase C or c-Jun nterminal kinase) causes a reduction in morphine, but not fentanyl tolerance 16, 26, 32.
Activation of different signaling cascades would limit the development of cross-tolerance
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between morphine (G-protein-dependent pathway) and fentanyl (β-arrestin -dependent
pathway).
The impact of differences in the duration of action between morphine and fentanyl
is less clear. Fentanyl produces a rapid (3 min) and short-lived (< 30 min)
antinociceptive effect compared to morphine microinjection into the vlPAG (peak effects
of 15-30 min and duration of 1-2 hours) 3. The short antinociceptive effect of fentanyl
may be caused by rapid internalization, which would limit signaling through G proteins.
This could explain the lack of cross-tolerance from fentanyl to morphine, but not from
morphine to fentanyl because prolonged G protein signaling by morphine should cause
adaptations that affect any MOPr bound ligand.
A final difference between the two drugs is how they are metabolized. Morphine is
metabolized into morphine-6-glucurunide or morphine-3-glucurunide, whereas there are
no known active metabolites of fentanyl 11, 13. The combined MOPr activation of
morphine and morphine-6-glucurunide may contribute to the development of tolerance.
Furthermore, morphine-3-glucurunide activation of TLR4 has been recently shown to
contribute to morphine tolerance within the PAG

11.

Once again, this difference may

contribute to differences in tolerance between morphine and fentanyl, but is unlikely to
prevent cross-tolerance between these drugs.
In conclusion, the current study shows a clear lack of cross-tolerance between
morphine and fentanyl when microinjected into the vlPAG. Although tolerance occurs
with co-administration of morphine and fentanyl into the vlPAG, cross-tolerance was
only evident to morphine not fentanyl. The implication of this research is that once
tolerance develops to a single opioid, co-administration of lower doses of two different
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opioid can be co-administered to achieve antinociception. These data support clinical
findings suggesting that co-administration of opioids is more effective than
administration of a single opioid whether it is morphine or fentanyl. The presence of
distinct tolerance mechanisms provides new targets for drug development to improve
pain treatment by limiting the development of tolerance.
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Figures

Figure 1. Location of injection sites within the vlPAG. Cannula placements for animals
pretreated with saline, morphine, fentanyl, or morphine+fentanyl. Injection sites were
similar for all groups across coronal sections of the PAG. Although the image shows the
location of the cannula tip, an injection volume of 0.4 µl causes the drug to diffuse into
the vlPAG. Distance from Lambda are listed below each image.
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Figure 2. Time course for antinociception following vlPAG morphine, fentanyl, and coadministration of morphine and fentanyl.Microinjection of morphine (5 μg/0.4 μL),
fentanyl (3 μg/0.4 μL), and combined morphine + fentanyl (2.5 μg + 1.5 μg/0.4 μL)
showed an increase in hot platency 5 min following vlPAG microinjection. Hot plate
latency remained elevated for 90 min following administration of morphine (N = 8-16) or
morphine and fentanyl (N = 8). In contrast, the increase in hot plate latency caused by
fentanyl (N = 8-15) administration had returned to near baseline levels within 30 min.
Not all rats were tested at all time points.
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Figure 3. Lack of cross-tolerance between vlPAG morphine, and fentanyl. Rats were
injected twice daily for two days with saline (0.4 μL), morphine (5 μg/0.4 μL), or fentanyl
(3 μg/0.4 μL) into the vlPAG. (a) The antinociceptive potency of morphine did not differ
between rats pretreated with fentanyl (N = 8) or saline (N = 8). (b) Likewise, the
antinociceptive potency of fentanyl did not differ between rats pretreated with morphine
(N = 7) or saline (N = 8).
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Figure 4. Co-administration of morphine and fentanyl cause cross-tolerance to morphine
but not fentanyl. (a) Repeated microinjections of morphine (2.5 μg/0.4 μL) and fentanyl
(1.5 μg/0.4 μL) into the vlPAG (N = 7) for two days caused a rightward shift in the
morphine dose response curve compared to saline pretreated rats (N = 7) as would be
expected with the development of tolerance. (b) In contrast, co-administration of
morphine and fentanyl (N = 8) had no effect on the fentanyl dose-response curve
compared to rats pretreated with saline (N = 8).
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Figure 5. Lack of tolerance to morphine and fentanyl combined following pretreatment
with morphine or fentanyl alone. (a) Twice daily microinjections of morphine (5 μg/0.4
μL) or fentanyl (5 μg/0.4 μL) for two days did not cause tolerance to the combination of
morphine+fentanyl. (b) Twice daily microinjections of morphine+fentanyl for two days
caused a rightward shift in the combined dose-response. (N = 8/group)
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